Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...

Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) ...

Irene Felux Brewer, born on May 30, 1953, in Floresville, Texas, passed away peacefully at South Arkansas Regional Hospital on Wednesday, Feb. 19, 2025, after a long battle with Non- Hodgkin’s ...

Horton was also named the Texans’ Ed Block Courage award winner in balloting from his teammates. The award is one of the most ...

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.

Jane Fonda is an incredibly strong woman who has been open and candid about her health over the years. The actress and ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Dan Bongino, podcaster and commentator, has been appointed deputy director of the FBI by President Donald Trump. Bongino, a ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

“I am thrilled to join Werewolf’s board of directors as the company advances its novel INDUKINE molecules through clinical development,” said Dr. Singhal. “Werewolf is demonstrating the power of the ...